Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook

Thelansis’s “Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Adenoid Cystic Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Overview

Advanced or metastatic adenoid cystic carcinoma (ACC) is a rare, slow-growing but relentlessly progressive malignancy arising predominantly from salivary glands — major and minor — and occasionally from lacrimal glands, tracheobronchial tree, and breast, characterised by insidious local invasion, perineural spread, and late-onset haematogenous metastasis — predominantly to lungs, bone, and liver. The molecular landscape is dominated by MYB-NFIB or MYBL1 fusion oncogenes — present in the majority of cases — dysregulating MYB transcriptional programmes alongside recurrent mutations in chromatin remodelling genes including KDM6A and ARID1A, and Notch pathway activation. Patients present with slow-growing masses, perineural pain, facial nerve dysfunction, and — in metastatic disease — progressive pulmonary nodules often remaining indolent for prolonged periods before symptomatic deterioration. Diagnosis integrates cross-sectional imaging, PET-CT for metastatic staging, and histopathological confirmation with molecular profiling. No globally approved systemic therapy exists for metastatic ACC; platinum-based chemotherapy yields modest responses, while targeted agents — including multikinase inhibitors lenvatinib and axitinib — demonstrate meaningful disease stabilisation in clinical practice. Notch pathway inhibitors and TRK inhibitors in NTRK-fusion-positive cases represent emerging therapeutic avenues. Definitive locoregional control with surgery and adjuvant radiotherapy remains paramount where feasible. Prognosis, despite indolent tempo, is ultimately poor in metastatic disease; multidisciplinary management, clinical trial enrolment, and patient-centred palliative support are indispensable to quality-focused care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)